ABL1 and leukemia: A recombinant yeast-based vaccine expressing the T315I-mutated BCR-ABL antigen was demonstrated to significantly reduce or eliminate BCR-ABL (T315I) leukemia cells from the peripheral blood of immunized animals and extended leukemia-free survival in a murine BCR-ABL + leukemia model[30].